Share Email Print

Proceedings Paper

Combined treatment of photodynamic therapy and the topoisomerase I inhibitor camptothecin in growing V79 and NHIK 3025 cells
Author(s): Jean-Michel Gaullier; Siv Kjersti Rodal; Johan Moan; Kristian Berg
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

The topoisomerase I (Topo I) inhibitor camptothecin (CPT) has been combined with photodynamic treatment (PDT) in V79 and NHIK 3025 cells. Meso-tetra (N-methyl-4-pyridyl) porphine (TMPyPH2) was used as a photosensitizer. The dye has been shown to localize in granules in the cytoplasm of both cell lines. Some of the granularly located TMPyPH2 is relocated to the cytosol after exposure to a light dose inactivation 70% of the cells. The human NHIK 3025 carcinoma from cervix were more resistant to PDT (D50 approximately equals 0.33 J/cm2) and CPT (D50 approximately equals 320 nM) than Chinese hamster V79 lung fibroblasts (PDT, D20 approximately equals 0.3 J/cm2 and CPT, D20 approximately equals 55 nM). When the cells were treated with CPT for 18 hours before PDT, the combination of treatments led to slight synergistic effects for low CPT concentrations (up to 100 nM in NHIK 3025 cells) and high PDT doses (above 0.15 J/cm2). For higher CPT concentrations and lower PDT doses, the combination of treatment became additive.

Paper Details

Date Published: 4 December 1996
PDF: 9 pages
Proc. SPIE 2924, Photochemotherapy: Photodynamic Therapy and Other Modalities II, (4 December 1996); doi: 10.1117/12.260775
Show Author Affiliations
Jean-Michel Gaullier, National Museum for Natural History (France)
Siv Kjersti Rodal, Institute for Cancer Research (Norway)
Johan Moan, Institute for Cancer Research (Norway)
Kristian Berg, Institute for Cancer Research (Norway)

Published in SPIE Proceedings Vol. 2924:
Photochemotherapy: Photodynamic Therapy and Other Modalities II
Stanley B. Brown; Benjamin Ehrenberg; Johan Moan, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?